<p>First Trust Advisors LP 在最近向证券交易委员会提交的文件中表示，在第二季度将其在波士顿科学公司（NYSE:BSX - 免费报告）的持股比例降低了 30.5%。该机构投资者在本季度出售了 188,265 股后，持有 429,637 股该医疗设备提供商的股票。根据其最近的 SEC 文件，First Trust Advisors LP 在波士顿科学的持股价值为 46,147,000 美元。</p>
<p>获取 <strong>波士顿科学</strong> 警报：</p>
<ul>
<li>注意死亡交叉：3 只股票触发了这一可怕信号</li>
</ul>
<p>其他机构投资者最近也对该公司的持仓进行了调整。先锋集团（Vanguard Group Inc.）在第二季度将其在波士顿科学的持股比例提高了 1.9%。先锋集团目前拥有 137,134,110 股该医疗设备提供商的股票，价值 14,729,575,000 美元，此前在上个季度又购买了 2,545,381 股。Geode Capital Management LLC 在第二季度将其在波士顿科学的持股提高了 2.0%。Geode Capital Management LLC 目前拥有 32,424,982 股该医疗设备提供商的股票，价值 3,466,320,000 美元，此前在上个季度又收购了 622,602 股。挪威银行（Norges Bank）在第二季度购买了波士顿科学的新股份，价值约为 2,089,937,000 美元。英维斯科（Invesco Ltd.）在第二季度将其在波士顿科学的持股提高了 1.4%。英维斯科目前拥有 16,851,518 股该医疗设备提供商的股票，价值 1,810,022,000 美元，此前在上个季度又收购了 226,578 股。最后，阿蒙迪（Amundi）在第一季度将其在波士顿科学的持股提高了 2.6%。阿蒙迪目前拥有 12,308,715 股该医疗设备提供商的股票，价值 1,212,408,000 美元，此前在上个季度又购买了 311,034 股。对冲基金和其他机构投资者持有该公司 89.07% 的股票。</p>
<h2>内部活动</h2>
<p>在其他波士顿科学的新闻中，董事 Ellen M. Zane 于 11 月 6 日星期四出售了 12,891 股公司的股票。该股票以 98.28 美元的平均价格出售，总价值为 1,266,927.48 美元。出售完成后，该董事直接持有 24,134 股公司的股票，价值约为 2,371,889.52 美元。这代表其持股比例下降了 34.82%。该出售在向证券交易委员会的文件中披露，可以通过此链接访问。此外，执行副总裁 Joseph Michael Fitzgerald 于 11 月 3 日星期一出售了 50,000 股该股票。该股票以 99.47 美元的平均价格出售，总价值为 4,973,500.00 美元。交易完成后，该执行副总裁直接持有 178,342 股公司的股票，价值 17,739,678.74 美元。该交易使其持股比例下降了 21.90%。有关此次出售的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士出售了 143,095 股公司股票，价值 14,228,950 美元。公司内部人士持有该公司 0.50% 的股票。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>3 只利用人工智能推动增长的医疗股</li>
</ul>
<p>BSX 已经成为几份研究报告的主题。Canaccord Genuity Group 在 10 月 23 日星期四的研究报告中重申了对波士顿科学的 “买入” 评级，并设定了 132.00 美元的目标价。Leerink Partners 在 10 月 1 日星期三的报告中将波士顿科学的目标价从 127.00 美元提高到 128.00 美元，并给予该公司 “跑赢大盘” 的评级。Evercore ISI 在 10 月 22 日星期三的研究报告中重申了对波士顿科学的 “跑赢大盘” 评级。Needham &amp; Company LLC 在 10 月 17 日星期五的研究报告中重申了 “买入” 评级，并设定了 121.00 美元的目标价。最后，Wall Street Zen 在 10 月 11 日星期六的研究报告中将波士顿科学的评级从 “持有” 上调至 “买入”。两位研究分析师对该股票给予了强烈买入评级，21 位分析师给予了买入评级，2 位分析师给予了持有评级。根据 MarketBeat.com 的数据，波士顿科学目前的平均评级为 “买入”，共识目标价为 123.77 美元。</p>
<p><strong>阅读我们关于 BSX 的最新报告</strong></p>
<h2>波士顿科学股票下跌 4.0%</h2>
<ul>
<li>3 个生物技术催化剂带来重大机会</li>
</ul>
<p>NYSE:BSX 周二开盘价为 93.66 美元。该公司的市值为 1388.4 亿美元，市盈率为 50.08，市盈率增长比率为 1.96，贝塔值为 0.67。波士顿科学公司的 12 个月低点为 85.98 美元，12 个月高点为 109.50 美元。该公司的流动比率为 1.51，速动比率为 0.96，债务股本比率为 0.47。该股票的 50 日简单移动平均为 99.20 美元，200 日简单移动平均为 101.95 美元。</p>
<p>波士顿科学（NYSE:BSX - 获取免费报告）最近在 10 月 22 日星期三发布了季度财报。该医疗设备提供商报告本季度每股收益为 0.75 美元，超出市场共识预期的 0.71 美元，超出幅度为 0.04 美元。波士顿科学的净利润率为 14.43%，股本回报率为 19.46%。该公司本季度的收入为 50.7 亿美元，而市场共识预期为 49.7 亿美元。去年同期，该公司每股收益为 0.63 美元。该公司的收入同比增长 20.3%。波士顿科学已将其 2025 财年的指导目标设定为每股收益 3.020-3.040 美元，2025 年第四季度的指导目标为每股收益 0.770-0.790 美元。分析师预计波士顿科学公司今年将发布每股收益 2.85 美元。</p>
<h2>波士顿科学公司简介</h2>
<p>（免费报告）</p>
<p>波士顿科学公司开发、制造和销售用于全球各类介入医学专业的医疗设备。它通过两个部门运营，分别是外科和心血管。该公司提供用于诊断和治疗胃肠道和肺部疾病的设备，如解决夹、胆道支架系统、支架和电切增强输送系统、直接可视化系统、数字导管和一次性十二指肠镜；用于治疗泌尿系统疾病的设备，包括输尿管支架、导管、篮子、导丝、鞘、气囊、一次性数字柔性输尿管镜、霍尔米激光系统、人工尿道括约肌、激光系统、光纤和水凝胶系统；以及用于治疗神经运动障碍和管理慢性疼痛的设备，如脊髓刺激器系统、专有编程软件、射频发生器、间接减压系统、实践优化工具和深脑刺激系统。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过波士顿科学</li>
<li>理解看涨期权交易量对成功期权交易的重要性</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的启示</li>
<li>三只提供优厚股息收益的天然气股票</li>
<li>三只最有可能在 2026 年拆分的股票</li>
<li>稀释每股收益（Diluted EPS）是什么？</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次充满活力</li>
</ul>
<p><strong>想看看其他对 BSX 感兴趣的对冲基金持有什么？</strong> 访问 HoldingsChannel.com，获取波士顿科学公司（NYSE:BSX - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在波士顿科学吗？</h2>
<p>在你考虑波士顿科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而波士顿科学并不在名单上。</p>
<p>尽管波士顿科学目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

波士顿科学

<p>First Trust Advisors LP 在第二季度减少了对波士顿科学公司的持股，减持幅度为 30.5%，出售了 188,265 股。其他机构投资者如先锋集团和 Geode Capital 则增加了他们的持股。内部人士的出售包括董事 Ellen M. Zane 和执行副总裁 Joseph Michael Fitzgerald。分析师维持 “买入” 评级，目标价共识为 123.77 美元。波士顿科学的股票开盘价为 93.66 美元，市值为 1388.4 亿美元</p>

<p>First Trust Advisors LP lowered its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 30.5% during the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor owned 429,637 shares of the medical equipment provider's stock after selling 188,265 shares during the quarter. First Trust Advisors LP's holdings in Boston Scientific were worth $46,147,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>First Trust Advisors LP 在最近向证券交易委员会提交的文件中表示，在第二季度将其在波士顿科学公司（NYSE:BSX - 免费报告）的持股比例降低了 30.5%。该机构投资者在本季度出售了 188,265 股后，持有 429,637 股该医疗设备提供商的股票。根据其最近的 SEC 文件，First Trust Advisors LP 在波士顿科学的持股价值为 46,147,000 美元。</p>
</div><p>Get <strong>Boston Scientific</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>波士顿科学</strong> 警报：</p>
</div><ul>
<li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>注意死亡交叉：3 只股票触发了这一可怕信号</li>
</ul>
</div><p>Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Boston Scientific by 1.9% in the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider's stock worth $14,729,575,000 after buying an additional 2,545,381 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider's stock worth $3,466,320,000 after acquiring an additional 622,602 shares in the last quarter. Norges Bank purchased a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $2,089,937,000. Invesco Ltd. boosted its position in shares of Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider's stock valued at $1,810,022,000 after acquiring an additional 226,578 shares during the last quarter. Finally, Amundi grew its holdings in shares of Boston Scientific by 2.6% in the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock valued at $1,212,408,000 after purchasing an additional 311,034 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者最近也对该公司的持仓进行了调整。先锋集团（Vanguard Group Inc.）在第二季度将其在波士顿科学的持股比例提高了 1.9%。先锋集团目前拥有 137,134,110 股该医疗设备提供商的股票，价值 14,729,575,000 美元，此前在上个季度又购买了 2,545,381 股。Geode Capital Management LLC 在第二季度将其在波士顿科学的持股提高了 2.0%。Geode Capital Management LLC 目前拥有 32,424,982 股该医疗设备提供商的股票，价值 3,466,320,000 美元，此前在上个季度又收购了 622,602 股。挪威银行（Norges Bank）在第二季度购买了波士顿科学的新股份，价值约为 2,089,937,000 美元。英维斯科（Invesco Ltd.）在第二季度将其在波士顿科学的持股提高了 1.4%。英维斯科目前拥有 16,851,518 股该医疗设备提供商的股票，价值 1,810,022,000 美元，此前在上个季度又收购了 226,578 股。最后，阿蒙迪（Amundi）在第一季度将其在波士顿科学的持股提高了 2.6%。阿蒙迪目前拥有 12,308,715 股该医疗设备提供商的股票，价值 1,212,408,000 美元，此前在上个季度又购买了 311,034 股。对冲基金和其他机构投资者持有该公司 89.07% 的股票。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the company's stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 143,095 shares of company stock valued at $14,228,950. Corporate insiders own 0.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他波士顿科学的新闻中，董事 Ellen M. Zane 于 11 月 6 日星期四出售了 12,891 股公司的股票。该股票以 98.28 美元的平均价格出售，总价值为 1,266,927.48 美元。出售完成后，该董事直接持有 24,134 股公司的股票，价值约为 2,371,889.52 美元。这代表其持股比例下降了 34.82%。该出售在向证券交易委员会的文件中披露，可以通过此链接访问。此外，执行副总裁 Joseph Michael Fitzgerald 于 11 月 3 日星期一出售了 50,000 股该股票。该股票以 99.47 美元的平均价格出售，总价值为 4,973,500.00 美元。交易完成后，该执行副总裁直接持有 178,342 股公司的股票，价值 17,739,678.74 美元。该交易使其持股比例下降了 21.90%。有关此次出售的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士出售了 143,095 股公司股票，价值 14,228,950 美元。公司内部人士持有该公司 0.50% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>3 Healthcare Stocks Using AI to Drive Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只利用人工智能推动增长的医疗股</li>
</ul>
</div><p>BSX has been the subject of several research reports. Canaccord Genuity Group reiterated a &#34;buy&#34; rating and set a $132.00 price objective on shares of Boston Scientific in a research report on Thursday, October 23rd. Leerink Partners increased their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the company an &#34;outperform&#34; rating in a report on Wednesday, October 1st. Evercore ISI reiterated an &#34;outperform&#34; rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Needham &amp; Company LLC restated a &#34;buy&#34; rating and set a $121.00 price objective on shares of Boston Scientific in a research report on Friday, October 17th. Finally, Wall Street Zen raised Boston Scientific from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, October 11th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Boston Scientific currently has an average rating of &#34;Buy&#34; and a consensus target price of $123.77.</p>
<div class="lb-trans"><p>BSX 已经成为几份研究报告的主题。Canaccord Genuity Group 在 10 月 23 日星期四的研究报告中重申了对波士顿科学的 “买入” 评级，并设定了 132.00 美元的目标价。Leerink Partners 在 10 月 1 日星期三的报告中将波士顿科学的目标价从 127.00 美元提高到 128.00 美元，并给予该公司 “跑赢大盘” 的评级。Evercore ISI 在 10 月 22 日星期三的研究报告中重申了对波士顿科学的 “跑赢大盘” 评级。Needham &amp; Company LLC 在 10 月 17 日星期五的研究报告中重申了 “买入” 评级，并设定了 121.00 美元的目标价。最后，Wall Street Zen 在 10 月 11 日星期六的研究报告中将波士顿科学的评级从 “持有” 上调至 “买入”。两位研究分析师对该股票给予了强烈买入评级，21 位分析师给予了买入评级，2 位分析师给予了持有评级。根据 MarketBeat.com 的数据，波士顿科学目前的平均评级为 “买入”，共识目标价为 123.77 美元。</p>
</div><p><strong>Read Our Latest Report on BSX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 BSX 的最新报告</strong></p>
</div><h2>Boston Scientific Stock Down 4.0%</h2>
<div class="lb-trans"><h2>波士顿科学股票下跌 4.0%</h2>
</div><ul>
<li>3 Biotech Catalysts Present Major Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>3 个生物技术催化剂带来重大机会</li>
</ul>
</div><p>NYSE:BSX opened at $93.66 on Tuesday. The company has a market cap of $138.84 billion, a price-to-earnings ratio of 50.08, a price-to-earnings-growth ratio of 1.96 and a beta of 0.67. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $99.20 and a 200-day simple moving average of $101.95.</p>
<div class="lb-trans"><p>NYSE:BSX 周二开盘价为 93.66 美元。该公司的市值为 1388.4 亿美元，市盈率为 50.08，市盈率增长比率为 1.96，贝塔值为 0.67。波士顿科学公司的 12 个月低点为 85.98 美元，12 个月高点为 109.50 美元。该公司的流动比率为 1.51，速动比率为 0.96，债务股本比率为 0.47。该股票的 50 日简单移动平均为 99.20 美元，200 日简单移动平均为 101.95 美元。</p>
</div><p>Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter last year, the firm posted $0.63 EPS. The firm's revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.</p>
<div class="lb-trans"><p>波士顿科学（NYSE:BSX - 获取免费报告）最近在 10 月 22 日星期三发布了季度财报。该医疗设备提供商报告本季度每股收益为 0.75 美元，超出市场共识预期的 0.71 美元，超出幅度为 0.04 美元。波士顿科学的净利润率为 14.43%，股本回报率为 19.46%。该公司本季度的收入为 50.7 亿美元，而市场共识预期为 49.7 亿美元。去年同期，该公司每股收益为 0.63 美元。该公司的收入同比增长 20.3%。波士顿科学已将其 2025 财年的指导目标设定为每股收益 3.020-3.040 美元，2025 年第四季度的指导目标为每股收益 0.770-0.790 美元。分析师预计波士顿科学公司今年将发布每股收益 2.85 美元。</p>
</div><h2>Boston Scientific Company Profile</h2>
<div class="lb-trans"><h2>波士顿科学公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.</p>
<div class="lb-trans"><p>波士顿科学公司开发、制造和销售用于全球各类介入医学专业的医疗设备。它通过两个部门运营，分别是外科和心血管。该公司提供用于诊断和治疗胃肠道和肺部疾病的设备，如解决夹、胆道支架系统、支架和电切增强输送系统、直接可视化系统、数字导管和一次性十二指肠镜；用于治疗泌尿系统疾病的设备，包括输尿管支架、导管、篮子、导丝、鞘、气囊、一次性数字柔性输尿管镜、霍尔米激光系统、人工尿道括约肌、激光系统、光纤和水凝胶系统；以及用于治疗神经运动障碍和管理慢性疼痛的设备，如脊髓刺激器系统、专有编程软件、射频发生器、间接减压系统、实践优化工具和深脑刺激系统。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Boston Scientific</li>
<li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过波士顿科学</li>
<li>理解看涨期权交易量对成功期权交易的重要性</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的启示</li>
<li>三只提供优厚股息收益的天然气股票</li>
<li>三只最有可能在 2026 年拆分的股票</li>
<li>稀释每股收益（Diluted EPS）是什么？</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次充满活力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BSX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 BSX 感兴趣的对冲基金持有什么？</strong> 访问 HoldingsChannel.com，获取波士顿科学公司（NYSE:BSX - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BSX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Boston Scientific Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在波士顿科学吗？</h2>
</div><p>Before you consider Boston Scientific, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑波士顿科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而波士顿科学并不在名单上。</p>
</div><p>While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管波士顿科学目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

First Trust Advisors LP 削减了其在波士顿科学公司$BSX 的股票持有量